Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Luca Antonioli1, Corrado Blandizzi2, Fabio Malavasi3

  • 1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ, USA.

Oncoimmunology
|October 21, 2016
PubMed

Related Concept Videos